



Boosting Health the Natural Way
Investor Presentation
March 2016

Forward looking statement

This presentation contains forward looking statements that involve risks and uncertainties.

Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Bioxyne Limited (Bioxyne) can give no assurance that these expectations will prove to be correct.

Actual results could differ materially from those anticipated. Reasons may include risks associated with product development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, risks associated with patent protection, future capital needs or other general risks or factors.

This document does not constitute an offer, solicitation or recommendation in relation to the subscription, purchase or sale of securities in any jurisdiction. Neither this presentation nor anything in it will form any part of any contract for the acquisition of securities.

Bioxyne

- Product development company based on proprietary strain of probiotic *Lactobacillus fermentum* VRI-003 (“PCC®”)
- Significant scientific and clinical data supports the marketing of the probiotic
- PCC® is currently manufactured in Denmark and PCC®-based products are sold in the US, Europe and parts of Asia
- A high gross margin business
- Potential deep product pipeline leveraging off our PCC® manufacturing and distribution experience and partnerships
- Potential to expand sales into China, India and other high probiotic growth geographies
- Further clinical studies to support expanded marketing and patent coverage


What are probiotics?

- Natural micro-organisms which provide a beneficial health effect by aiding digestion and/or by triggering the immune system
- Probiotic products may contain a single strain or many strains, and the number of organisms in a daily dose can range from 1 billion to more than 250 billion
- Most common bacteria are strains of *Lactobacillus* and *Bifidobacteria*
- Not all probiotic strains are effective – clinical evidence is needed to support health claims

Probiotic industry – Growth opportunities

- The probiotic ingredients market is estimated to be valued at US\$33 billion in 2015
- It is projected to reach US\$47 billion by 2020
- This represents a CAGR of 7.0%
- The Asia-Pacific market is projected to grow at the highest CAGR esp. in countries such as India and China

Probiotic Ingredients Market Size, by Region, 2015 vs 2020 (USD Million)




Source: MarketsandMarkets Analysis

E – Estimated, P - Projected

source: MarketsandMarkets 2015


Probiotic industry – Growth opportunities

- Growth in probiotics not consistent across geographies.
- very strong growth in China, Brazil, Canada, and Spain.



Lactobacillus fermentum VRI-003 (PCC®)

PCC® is Bioxyne's patented probiotic strain *Lactobacillus fermentum* VRI-003



PCC® features and benefits



Feature	Benefit
Stable at room temperature	Refrigeration not required to maintain biological activity
Resistant to bile acids, pepsin, & low pH	Can be supplied in standard capsules or as a powder
Adheres to GI tract	Long-lasting effects
Ability to colonise GI tract	
Human origin	Adapted to the human gastrointestinal tract
Inhibits human GI pathogens, including bacteria & fungi	Restores healthy gut function
Binds to Peyer's patches in the gut and activates the Th1 immune response	Promotes mucosal immunity – for skin and respiratory health

PCC[®] is effective in boosting human health

- Clinical studies indicate that PCC[®] may have beneficial effects in boosting immune health:
 - Reduces respiratory infections in elite (male) athletes¹
 - Enhances immune response to the flu vaccine²
 - Alleviates symptoms of atopic dermatitis in infants³

¹ Cox *et al.* 2008; West *et al.* 2011

² French and Penny 2009

³ Weston *et al.* 2005


PCC® is safe

- Used since 2002, with no reported consumer adverse effects
- Tested in clinical studies in doses up to 12 billion CFU/day, with no reported serious adverse events
- The USFDA has granted *Lactobacillus* and *Bifidobacteria* “generally regarded as safe” (GRAS) status
- *Lactobacillus fermentum* has been granted Qualified Presumption of Safety (QPS) status since 2007 by the European Food Safety Authority (EFSA)
- A “young” and award-winning strain

In 2010 at Health Ingredients Europe, the PCC® strain won the prestigious *Health Ingredients Excellence Award* in the Sports Performance category.

Bioxyne wholesales PCC® globally

- PCC® is the active ingredient in existing products distributed globally
- Active ingredient manufactured by industry leader
- Products manufactured and distributed in USA, Europe and South East Asia via key industry relationships



Chr Hansen – Manufacturer AND customer

CHR HANSEN

Improving food & health


- Proven world class GMP production capability
- Trusted global supplier of lactic acid bacteria for more than a century
- Bioxyne's strategic relationship provides access to:
 - Certified and authorized production sites in Denmark
 - State-of-the-art production facilities, providing live and stable probiotics at a fixed price per kg of active ingredient
 - Analysis, control and release of safe probiotic products with adequate cell counts
 - Safe delivery to end customer

Chr Hansen – Manufacturer AND customer *cont'd*

- Chr Hansen is a growing distributor of products using PCC – Bioxyne receives a royalty from these sales
- Both Bioxyne and Chr Hansen are committed to maintaining a close and continuing supply arrangement with competitive pricing and high quality production of PCC®


Nu-Skin – Key customer

- Nu-Skin Enterprises (*NYSE:NUS*) is a US-based direct selling and multilevel marketing business
- Develops and distributes anti-aging personal care products and dietary supplements
- Nu-Skin's products are marketed through the Pharmanex brand



Current and potential markets for PCC®

- Dietary supplements (**current market**)
- Functional Food
- Infant formula
- Biopharmaceuticals
- Veterinary



While all segments are expected to grow over the coming years, industry commentary tends to emphasize growth within the animal feed market.

Products being considered for the Australian market in 2016*

- Progastrim (capsules) – for intestinal health
- proTract AD (sachets) to manage the symptoms of atopic dermatitis in infants

*Subject to appropriate regulatory and manufacturing considerations being satisfied

Functional food opportunities

- Potential PCC-based food products
 - Infant formula
 - Margarine / spreads
 - Health food bars
 - Chocolates
 - Fermented drinks
 - Yoghurt
 - Oils

Potential new clinical studies using PCC®

- Gastrointestinal health in healthy population – microbiome shift after sustained dosing
- Effect on vaginal candidiasis
- Effect on weight loss
- Effect on mood

Title	Territory	Patent no.	Status	Priority Date
Probiotic Bacterium <i>Lactobacillus fermentum</i>	Australia	2003245473	Granted	17-Feb-03
	Australia	2003258366	Granted	08-Sep-03
	Brazil		Pending	06-Sep-02
	Canada	2497989	Granted	08-Sep-02
	China	ZL03823833.0	Granted	08-Sep-02
	Europe	1539927	Granted	08-Sep-02
	Japan	4455333	Granted	08-Sep-02
	New Zealand	538640	Granted	08-Sep-02
	Singapore	200501398.2	Granted	08-Sep-02
Composition and Treatments of Skin Disorders	Europe	1482959	Granted	17-Feb-02

Historical financial performance


- Renewed sales focus on PCC® development since 2013
- Sales and distribution through existing wholesale customer base successfully increased
- Tight focus on cost management and incremental earnings to increase cash reserves to further develop PCC®

	FY13	FY14	FY15	1/7/15 - 29/2/16
Revenue	\$880,497	\$2,304,921	\$1,492,701	\$1,468,329
Gross Profit	\$478,329	\$1,063,696	\$926,690	\$847,651
Net Profit/(Loss)	(\$221,671)	\$169,015	\$201,039	\$417,550


Balance Sheet, Cash and Equity Reserves

- ASX Listed – (ASX:BXN)
- Current (March 2016) cash reserves > \$1.4m
- Balance sheet values strategic investment in Mariposa Health Inc.
at cost (\$325,000) – current indicators of potential listing price
value this at > \$900,000;
- 200,343,101 shares on issue:
 - Current market capitalisation (8 March 2016 share price \$0.023) = \$4,607,891
 - Recent share price movements > \$0.03) equate to capitalisation > \$6,000,000


Value drivers and Vision



5 Year Vision – Product and Sales Growth




Year 1 – Resource, consolidate, build



Years 2 – 5

Growth through sales and product acquisition



Bioxyne Limited – People

● Non-Executive

- Mr Tony Ho (Chairman)
- Mr Patrick Ford (Director)
- Mr George Cameron-Dow
(Director)
- Sydney and Perth presence
- Low overhead structure

● Executive Team

- Dr Peter French (Executive Director)
- Mr Jarrod White (CFO and Co Sec)
- Mr Ashok Jairath (Sales Manager)


Share register – Top 20

Top Holders Snapshot - Grouped

Composition : ORD

Rank	Name	Units	% of Units
1.	ONDEK PTY LTD	39,868,277	19.90
2.	WIGRAM TRADING PTY LIMITED	17,457,671	8.71
3.	PT SOHO INDUSTRI PHARMASI	9,678,085	4.83
4.	PROF ROBERT LLEWELLYN CLANCY + MRS CHRISTINE MARY CLANCY <CLANCY SUPER FUND NO 2 A/C>	9,564,390	4.77
5.	MR ANTHONY HO + MS CHUI HO	8,400,000	4.19
6.	MR MAKRAM HANNA + MRS RITA HANNA <HANNA & CO P/L SUPER A/C>	8,363,000	4.17
7.	P FORD SUPERANNUATION PTY LTD <PATRICK FORD SUPER FUND A/C>	8,000,000	3.99
8.	SOUTHAM INVESTMENTS 2003 PTY LTD <WARWICKSHIRE INVESTMENT A/C>	7,681,419	3.83
9.	CALAMA HOLDINGS PTY LTD <MAMBAT SUPER FUND A/C>	4,893,536	2.44
10.	NEWCASTLE INNOVATION LIMITED	3,668,125	1.83
11.	MR PAUL BOUDEWYN EDWARD BOLT	2,998,125	1.50
12.	JETOSEA PTY LTD	2,694,713	1.35
13.	MR GEN CHANG JEFFERY TAY	2,023,033	1.01
14.	OCTIFIL PTY LTD	2,018,448	1.01
15.	SYMINGTON PTY LTD	2,000,000	1.00
16.	IMMUNE INVESTMENTS PTY LTD <MRS TJ'S A/C>	1,966,542	0.98
17.	MCKELL PLACE NOMINEES PTY LTD	1,600,000	0.80
18.	MR MARK JAMES STEMMER	1,596,448	0.80
19.	MR BO XU	1,505,000	0.75
20.	LYNDCOTE HOLDINGS PTY LTD	1,490,949	0.74
Totals: Top 20 holders of ISSUED CAPITAL		137,467,761	68.62
Total Remaining Holders Balance		62,875,340	31.38

Share price – 2 Year performance





Bioxyme

Boosting Health the Natural Way